First Albany Keeps 'Buy' on Human Genome

Analyst David Webber thinks an antibody to treat anthrax complements the biotech firm's promising pipeline

First Albany keeps its buy rating on Human Genome Sciences (HGSI ).

To continue reading this article you must be a Bloomberg Professional Service Subscriber.